Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00093171 | Study Evaluating rFIX; BeneFIX® in Hemophilia B | PHASE3 | COMPLETED | 23 | — | — | - | May 1, 2005 | Aug 21, 2009 | 7 | United States |
| NCT00093210 | Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B | PHASE3 | COMPLETED | - | — | — | - | Sep 1, 2005 | Dec 5, 2007 | - | — |
| Name | Type | Description |
|---|---|---|
| rFIX | DRUG | - |
| rFIX-R | DRUG | - |
Inclusion Criteria: * Hemophilia B (FIX:C less than 2%) * Previous treatment of at least 150 exposure days using any FIX product * 12 years of age and older Exclusion Criteria: * The patient has a currently detectable factor IX inhibitor or a history of inhibitors. (A family history of inhibitors...